Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Pau Castel, Eneda Toska, Zachary S Zumsteg, F Javier Carmona, Moshe Elkabets, Ana Bosch & Maurizio Scaltriti. (2014) Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Molecular & Cellular Oncology 1:3.
Read now
Read now
Articles from other publishers (12)
Georg Hess, Karola Wagner, Ulrich Keller, Paul La Rosee, Johannes Atta, Kai Hübel, Christian Lerchenmueller, Daniel Schoendube, Mathias Witzens-Harig, Christian Ruckes, Christoph Medler, Christina van Oordt, Wolfram Klapper, Matthias Theobald & Martin Dreyling. (2020) Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. HemaSphere 4:3, pages e398.
Crossref
Crossref
Urte Gayko, Mann Fung, Fong Clow, Steven Sun, Elizabeth Faust, Samiyeh Price, Danelle James, Margaret Doyle, Samina Bari & Sen Hong Zhuang. (2015) Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. Annals of the New York Academy of Sciences 1358:1, pages 82-94.
Crossref
Crossref
Nada Chaoul, Catherine Fayolle, Belinda Desrues, Marine Oberkampf, Alexandre Tang, Daniel Ladant & Claude Leclerc. (2015) Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication. Cancer Research 75:16, pages 3279-3291.
Crossref
Crossref
G Hess, U Keller, C W Scholz, M Witzens-Harig, J Atta, C Buske, S Kirschey, C Ruckes, C Medler, C van Oordt, W Klapper, M Theobald & M Dreyling. (2015) Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 29:8, pages 1695-1701.
Crossref
Crossref
Mirna Mourtada-Maarabouni & Gwyn T. Williams. (2014) Role of GAS5 Noncoding RNA in Mediating the Effects of Rapamycin and Its Analogues on Mantle Cell Lymphoma Cells. Clinical Lymphoma Myeloma and Leukemia 14:6, pages 468-473.
Crossref
Crossref
Jerauld S. Skotnicki & Magid A. Abou-Gharbia. 2014. Orphan Drugs and Rare Diseases. Orphan Drugs and Rare Diseases
347
366
.
Bertrand Coiffier. (2013) Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 13:4, pages 351-359.
Crossref
Crossref
Kennosuke Karube, Shinobu Tsuzuki, Noriaki Yoshida, Kotaro Arita, Harumi Kato, Miyuki Katayama, Young-Hyeh Ko, Koichi Ohshima, Shigeo Nakamura, Tomohiro Kinoshita & Masao Seto. (2013) Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate. Cancer Letters 333:1, pages 47-55.
Crossref
Crossref
Krimo Bouabdallah, Vincent Ribrag, Louis Terriou, Jean-Charles Soria & Richard Delarue. (2013) Temsirolimus in the treatment of mantle cell lymphoma. Current Opinion in Oncology 25:Supplement 2, pages S1-S12.
Crossref
Crossref
Pauline Brice & Catherine ThieblemontS. Le Gouill & A. Moreau. 2013. Actualités thérapeutiques dans les lymphomes. Actualités thérapeutiques dans les lymphomes
103
123
.
Pedro Jares, Dolors Colomer & Elias Campo. (2012) Molecular pathogenesis of mantle cell lymphoma. Journal of Clinical Investigation 122:10, pages 3416-3423.
Crossref
Crossref
Sushma Vemulapalli, Alain Mita, Yesid Alvarado, Kamalesh Sankhala & Monica Mita. (2011) The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Targeted Oncology 6:1, pages 29-39.
Crossref
Crossref